Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22375523 | 1.00 | FOLH1 (0.40) | FOLH1GSRCPB2SIRT6SIRT1 | |
| SCHEMBL20402783 | 0.98 | CPB2 (0.41) | FOLH1GSRCPB2SIRT6SIRT1 | |
| SCHEMBL24658920 | 0.87 | FOLH1 (0.39) | FOLH1GSRCPB2SIRT6SIRT1 | |
| SCHEMBL22859968 | 0.85 | FOLH1 (0.40) | FOLH1GSRCPB2SIRT6SIRT1 | |
| SCHEMBL10047161 | 0.85 | FOLH1 (0.40) | FOLH1GSRCPB2SIRT6SIRT1 | |
| SCHEMBL13891963 | 0.85 | FOLH1 (0.40) | FOLH1GSRCPB2SIRT6SIRT1 | |
| SCHEMBL19483433 | 0.84 | CPB2 (0.41) | FOLH1GSRCPB2SIRT6SIRT1 | |
| SCHEMBL19483432 | 0.84 | CPB2 (0.41) | FOLH1GSRCPB2SIRT6SIRT1 | |
| SCHEMBL21566733 | 0.82 | SIRT6 (0.52) | FOLH1GSRCPB2SIRT6SIRT1 | |
| SCHEMBL24379977 | 0.82 | FOLH1 (0.41) | FOLH1GSRCPB2SIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174985-A1 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | NEUBASE THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174985-A1 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | TARDBP, SARNP, SNRPE | FOLH1 1495/4885GSR 2434/4885CPB2 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.